GDC-9545

Chemical Name:

Giredestrant, also known as GDC-9545 and RG6171, is a SERD. GDC-9545 is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD GDC-9545 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation.

SMILES Code: 

C[C@@H]1CC(C2=C(N3)C=CC=C2)=C3[C@@H](C4=C(C=C(C=C4F)NC5CN(C5)CCCF)F)N1CC(CO)(F)F

InChi Code:

InChI=1S/C27H31F5N4O/c1-16-9-20-19-5-2-3-6-23(19)34-25(20)26(36(16)14-27(31,32)15-37)24-21(29)10-17(11-22(24)30)33-18-12-35(13-18)8-4-7-28/h2-3,5-6,10-11,16,18,26,33-34,37H,4,7-9,12-15H2,1H3/t16-,26-/m1/s1

InChi Key:

GQCXHIKRWBIQMD-AKJBCIBTSA-N

Keyword:

1953133-47-5；CAS:1953133-47-5；CAS：1953133-47-5；GDC-9545; GDC9545; GDC 9545; RG6171; RG-6171; RG 6171; Giredestrant

Solubility: Soluble in DMSO

Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Description: 

Giredestrant, also known as GDC-9545 and RG6171, is a SERD. GDC-9545 is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD GDC-9545 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation.

Target: Selective ER antagonists